Stockscreener 앱 받기
9.61
2.78%
0.26
시간 외 거래:
9.80
0.19
+1.98%
전일 마감가:
$9.35
열려 있는:
$9.69
하루 거래량:
482.27K
Relative Volume:
0.73
시가총액:
$868.03M
수익:
-
순이익/손실:
$-56.88M
주가수익비율:
-14.55
EPS:
-0.6604
순현금흐름:
$-39.43M
1주 성능:
+4.00%
1개월 성능:
-7.24%
6개월 성능:
+99.79%
1년 성능:
+224.66%
1일 변동 폭
$9.58
$9.88
1주일 범위
$9.21
$10.20
52주 변동 폭
$2.85
$11.62
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Compare DRTS vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRTS
Alpha Tau Medical Ltd
|
9.61 | 873.45M | 0 | -56.88M | -39.43M | -0.6604 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-12-15 | 개시 | Citigroup | Buy |
| 2023-04-24 | 개시 | H.C. Wainwright | Buy |
| 2022-04-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-04-08 | 개시 | Piper Sandler | Overweight |
| 2022-04-04 | 개시 | Citigroup | Buy |
모두보기
Alpha Tau Medical Ltd 주식(DRTS)의 최신 뉴스
H.C. Wainwright reiterates Alpha Tau Medical stock rating on FDA trial clearance - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
Alpha Tau Medical: A Lot Of Shots On Goal (NASDAQ:DRTS) - Seeking Alpha
Alpha Tau Receives FDA Clearance to Complete Enrollment in REGAIN Recurrent Glioblastoma Trial and Add Two U.S. Clinical Sites; Early Interim Results Showed 100% Local Disease Control - The Manila Times
Alpha Tau (NASDAQ: DRTS) gets FDA clearance to complete REGAIN glioblastoma trial enrollment - Stock Titan
Alpha Tau Receives FDA Clearance to Complete Enrollment in - GlobeNewswire
Alpha Tau Medical sets up catalyst-rich 2026 as key cancer trial data nears - MSN
Barclays Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Raises Target Price to $17 - Moomoo
Insider Sell: Raphi Levy Sells 32,500 Shares of Alpha Tau Medica - GuruFocus
Alpha Tau Medical (DRTS) CFO Levy Raphi sells 32,500 shares in open-market trades - Stock Titan
Alpha Tau,Tolmar Team Up to Bring Alpha DaRT Therapy to U.S. Prostate Cancer Patients - Imaging Technology News
[144] Alpha Tau Medical Ltd. SEC Filing - Stock Titan
Alpha Tau Medical and Tolmar partner to commercialise Alpha DaRT prostate cancer therapy in the US - Health Tech World
H.C. Wainwright Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Alpha Tau Medical Rises on Tolmar Deal to Commercialize Prostate Cancer Therapy - Moomoo
Alpha Tau teams with Tolmar on lucrative prostate cancer dealGlobes - Globes - Israel Business News
DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing - Yahoo Finance
Alpha Tau Medical, Tolmar International Agree to Develop, Commercialize Prostate Cancer Therapy - Moomoo
Alpha Tau Strikes 20-Year U.S. Prostate Cancer Commercialization and $20 Million Equity Deal With Tolmar - TipRanks
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients - The Manila Times
Alpha Tau (DRTS) lands Tolmar partnership with $20M equity and milestones - Stock Titan
New prostate cancer radiation option backed by $35M Alpha Tau–Tolmar deal - Stock Titan
H.C. Wainwright reiterates Alpha Tau Medical stock rating on trial data - Investing.com UK
Number of shareholders of Alpha Tau Medical Ltd. – NASDAQ:DRTSW - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Barclays Maintains Alpha Tau Medical(DRTS.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Alpha Tau Medical Reports Data Showing Alpha DaRT Increases Overall Survival for Patients With Pancreatic Cancer - Moomoo
Alpha Tau Posts Strong Pancreatic Cancer Survival Data for Alpha DaRT at 2026 ASCO - TipRanks
Alpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting - The Manila Times
Alpha Tau trial links one-time pancreatic treatment to 11‑month survival - Stock Titan
Pancreatic survival data highlight Alpha Tau (NASDAQ: DRTS) Alpha DaRT trials - Stock Titan
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears - Yahoo Finance
DRTS Initiated Coverage by BarclaysRating Overweight with Tar - GuruFocus
DRTSW Holds Above Key Support After Modest DeclineWatchlist Stock Ideas - The Legal Advocate
DRTS: Key cancer trials advance with pivotal data expected in 2026; strong financial position maintained - TradingView
Barclays Initiates Alpha Tau Medical With Overweight Rating, $15 Price Target - marketscreener.com
Barclays initiates Alpha Tau Medical stock with overweight rating By Investing.com - Investing.com Nigeria
Barclays initiates Alpha Tau Medical stock with overweight rating - Investing.com
Analysts Offer Insights on Healthcare Companies: Alpha Tau Medical Ltd (DRTS), Neurogene (NGNE) and Milestone Pharmaceuticals (MIST) - The Globe and Mail
Alpha Tau Medical (DRTS) Sheds 2.70% as Stock Tests Key Support ZoneValue Factor - thelegaladvocate.com
Alpha Tau Medical (DRTS) Slides 8.4% as Shares Test Support LevelsScalping Stock Signals - thelegaladvocate.com
Alpha Tau Medical stock surges as interim brain tumor trial data sparks rally - MSN
DRTS Reiterated by HC Wainwright & Co. -- Price Target Maintained at $15 - GuruFocus
Alpha Tau Medical shares early Regain data: 2 complete responses in glioblastoma study - MSN
H.C. Wainwright reiterates Buy on Alpha Tau stock, $15 target - Investing.com India
Alpha Tau Medical Ltd (DRTS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):